Genzyme
Sanofi’s rare disease division includes Genzyme, one of the world's leading biotechnology companies. Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since its founding in 1981, the company has introduced breakthrough treatments across several areas of medicine that have provided new hope for patients.
Our products are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and immune disease. The company's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. Genzyme is part of the Sanofi Group.
Commitment to patients
We are mindful of our responsibility to all of our stakeholders, including patients, physicians, shareholders, employees and our communities. We are driven, first and always, by our commitment to patients and exist to innovate on behalf of people with serious diseases and to meet major unmet medical needs. This commitment includes all patients, regardless of their location or financial circumstances. Genzyme has a strong presence in developing countries, where we work with physicians and governments to build sustainable health care systems and provide free medicine to patients in countries where those systems do not yet exist.
Updated: November 21, 2011
